Global Xerostomia (Dry Mouth) Therapeutics Market Report, History and Forecast 2018-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global Xerostomia (Dry Mouth) Therapeutics Market Report, History and Forecast 2018-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application
Xerostomia (Dry Mouth) Therapeutics report published by QYResearch reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Xerostomia (Dry Mouth) Therapeutics market is projected to reach US$ 837.9 million in 2034, increasing from US$ 684 million in 2022, with the CAGR of 2.9% during the period of 2024 to 2034. Demand from OTC and Prescription are the major drivers for the industry.
North America, Europe and Asia Pacific are the key regions for Xerostomia (Dry Mouth) Therapeutics industry. Among those areas, stimulated by rigid demand from downstream industries, Asia Pacific is estimated to experience fast growth, with the CAGR of % during 2024 to 2034.
Globally, Xerostomia (Dry Mouth) Therapeutics key manufacturers include GlaxoSmithKline plc, Church & Dwight, Inc., Colgate-Palmolive Company, Hikma Pharmaceuticals PLC, Pendopharm, Sun Pharmaceuticals Industries Ltd., Lupin Pharmaceuticals, Inc., Pfizer, Inc. and Parnell Pharmaceuticals, Inc., etc. GlaxoSmithKline plc, Church & Dwight, Inc., Colgate-Palmolive Company are top 3 players and held % sales share in total in 2022.
Xerostomia (Dry Mouth) Therapeutics can be divided into Salivary Stimulants, Salivary Substitutes and Dentifrices,, etc. Salivary Stimulants is the mainstream product in the market, accounting for % sales share globally in 2022.
Xerostomia (Dry Mouth) Therapeutics is widely used in various fields, such as OTC and Prescription, etc. OTC provides greatest supports to the Xerostomia (Dry Mouth) Therapeutics industry development. In 2022, global % sales of Xerostomia (Dry Mouth) Therapeutics went into OTC filed.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Xerostomia (Dry Mouth) Therapeutics market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Manufacturers, Type, Application and Regions Listed in the Report
GlaxoSmithKline plc
Church & Dwight, Inc.
Colgate-Palmolive Company
Hikma Pharmaceuticals PLC
Pendopharm
Sun Pharmaceuticals Industries Ltd.
Lupin Pharmaceuticals, Inc.
Pfizer, Inc.
Parnell Pharmaceuticals, Inc.
Acacia Pharma
OraCoat
Segment by Type
Salivary Stimulants
Salivary Substitutes
Dentifrices
OTC
Prescription
North America
United States
Canada
Mexico
Europe
Germany
France
UK
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Brazil
Middle East & Africa
Turkey
Saudi Arabia
UAE
Each chapter of the report provides detailed information for readers to understand the Xerostomia (Dry Mouth) Therapeutics market further
Chapter 1Product Definition, Product Types, Volume and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 2Manufacturer Competition Status, including Sales and Revenue comparison, Manufacturers’ commercial date of Xerostomia (Dry Mouth) Therapeutics, product type offered by each manufacturer, Mergers & Acquisitions activities, Expansion activities occurred in the Xerostomia (Dry Mouth) Therapeutics industry.
Chapter 3Historical (2018-2022) and forecast (2024-2034) volume and revenue analysis of Xerostomia (Dry Mouth) Therapeutics in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.
Chapter 4Product Application, Volume and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 5 to 9Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa, including volume and revenue analysis.
Chapter 10Manufacturers’ Outline, covering company’s basic information like headquarter, contact information, major business, Xerostomia (Dry Mouth) Therapeutics introduction, etc. Xerostomia (Dry Mouth) Therapeutics Sales, Revenue, Price and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 11Industry Chain, like raw materials, manufacturing cost, are covered. In addition, market opportunities and challenges are emphasized as well in the chapter.
Chapter 12Market Channel, Distributors and Customers are listed.
Chapter 13QYResearch’s Conclusions of Xerostomia (Dry Mouth) Therapeutics market based on comprehensive survey.
Chapter 14Methodology and Data Sources adopted by QYResearch.
North America, Europe and Asia Pacific are the key regions for Xerostomia (Dry Mouth) Therapeutics industry. Among those areas, stimulated by rigid demand from downstream industries, Asia Pacific is estimated to experience fast growth, with the CAGR of % during 2024 to 2034.
Globally, Xerostomia (Dry Mouth) Therapeutics key manufacturers include GlaxoSmithKline plc, Church & Dwight, Inc., Colgate-Palmolive Company, Hikma Pharmaceuticals PLC, Pendopharm, Sun Pharmaceuticals Industries Ltd., Lupin Pharmaceuticals, Inc., Pfizer, Inc. and Parnell Pharmaceuticals, Inc., etc. GlaxoSmithKline plc, Church & Dwight, Inc., Colgate-Palmolive Company are top 3 players and held % sales share in total in 2022.
Xerostomia (Dry Mouth) Therapeutics can be divided into Salivary Stimulants, Salivary Substitutes and Dentifrices,, etc. Salivary Stimulants is the mainstream product in the market, accounting for % sales share globally in 2022.
Xerostomia (Dry Mouth) Therapeutics is widely used in various fields, such as OTC and Prescription, etc. OTC provides greatest supports to the Xerostomia (Dry Mouth) Therapeutics industry development. In 2022, global % sales of Xerostomia (Dry Mouth) Therapeutics went into OTC filed.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Xerostomia (Dry Mouth) Therapeutics market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Manufacturers, Type, Application and Regions Listed in the Report
By Company
GlaxoSmithKline plc
Church & Dwight, Inc.
Colgate-Palmolive Company
Hikma Pharmaceuticals PLC
Pendopharm
Sun Pharmaceuticals Industries Ltd.
Lupin Pharmaceuticals, Inc.
Pfizer, Inc.
Parnell Pharmaceuticals, Inc.
Acacia Pharma
OraCoat
Segment by Type
Salivary Stimulants
Salivary Substitutes
Dentifrices
Segment by Application
OTC
Prescription
Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
UK
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Brazil
Middle East & Africa
Turkey
Saudi Arabia
UAE
Each chapter of the report provides detailed information for readers to understand the Xerostomia (Dry Mouth) Therapeutics market further
Chapter 1Product Definition, Product Types, Volume and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 2Manufacturer Competition Status, including Sales and Revenue comparison, Manufacturers’ commercial date of Xerostomia (Dry Mouth) Therapeutics, product type offered by each manufacturer, Mergers & Acquisitions activities, Expansion activities occurred in the Xerostomia (Dry Mouth) Therapeutics industry.
Chapter 3Historical (2018-2022) and forecast (2024-2034) volume and revenue analysis of Xerostomia (Dry Mouth) Therapeutics in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.
Chapter 4Product Application, Volume and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 5 to 9Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa, including volume and revenue analysis.
Chapter 10Manufacturers’ Outline, covering company’s basic information like headquarter, contact information, major business, Xerostomia (Dry Mouth) Therapeutics introduction, etc. Xerostomia (Dry Mouth) Therapeutics Sales, Revenue, Price and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 11Industry Chain, like raw materials, manufacturing cost, are covered. In addition, market opportunities and challenges are emphasized as well in the chapter.
Chapter 12Market Channel, Distributors and Customers are listed.
Chapter 13QYResearch’s Conclusions of Xerostomia (Dry Mouth) Therapeutics market based on comprehensive survey.
Chapter 14Methodology and Data Sources adopted by QYResearch.
Electronic and Semiconductor
Food and Beverages
Chemicals and Materials
Consumer Goods
Construction Manufacturing
Aerospace and Defence
Energy and Power
ICT Media
Banking and Finance
Automotive and Transportation
Machinery and Equipments
Pharmaceutical and Healthcare
Medical Devices